Elaprase 2017 U.S. PROMOTIONAL AUDIT REPORT

Elaprase 2017 U.S. PROMOTIONAL AUDIT REPORT

  • July 2018 •
  • 24 pages •
  • Report ID: 5210293 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Elaprase through reportable promotional activity in 2017 to drive use within the Mucopolysaccharidosis Type II market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Shire’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Hematology/Oncology, Family Medicine, Internal Medicine, and Gastroenterology) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Elaprase throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Elaprase in 2017?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 800 paid interactions across 400 physicians made on behalf of Elaprase were carefully examined to support our analysis.